NCT03936465View on ClinicalTrials.gov

Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

41

Participants

Timeline

Start Date

September 27, 2019

Primary Completion Date

March 16, 2024

Study Completion Date

October 1, 2024

Conditions
Solid Tumor, ChildhoodLymphomaBrain Tumor, Pediatric
Interventions
DRUG

BMS-986158

BMS-986158 belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.

DRUG

BMS-986378

BMS-986378 (also known as CC-90010) belongs to a group of drugs called Bromodomain (BRD) and Extra-Terminal Domain (BET) inhibitors. These drugs block proteins that are important in reading DNA, which is a process important for cancer cells.

Trial Locations (6)

27710

Duke University Medical Center, Durham

45229

Cincinnati Children's Hospital Medical Center, Cincinnati

48109

C.S. Mott Children's Hospital, Ann Arbor

98105

Seattle Children's Hospital, Seattle

02115

Dana Farber Cancer Institute, Boston

M5G 1X8

Hospital for Sick Children, Toronto

All Listed Sponsors
collaborator

Stand Up To Cancer

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT03936465 - Study of the Bromodomain (BRD) and Extra-Terminal Domain (BET) Inhibitors BMS-986158 and BMS-986378 in Pediatric Cancer | Biotech Hunter | Biotech Hunter